| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||||||||||
Net loss | ||||||||||||||||
45,535 | 66,858 | -11,274 | -200,408 | -185,089 | -164,981 | -117,250 | -91,247 | -75,182 | -68,357 | -51,400 | -41,386 | -36,235 | -23,202 | 0 | 0 | 0 |
Reconciliation of net loss to net cash used in operating activities: | ||||||||||||||||
Depreciation and amortization | ||||||||||||||||
6,004 | 4,725 | 4,238 | 3,838 | 3,505 | 3,519 | 3,380 | 3,289 | 3,130 | 3,024 | 2,630 | 2,074 | 1,539 | 925 | 0 | 0 | 0 |
Equity-based compensation | ||||||||||||||||
48,537 | 44,057 | 45,225 | 41,936 | 39,074 | 34,985 | 28,939 | 25,753 | 21,155 | 18,873 | 15,922 | 13,347 | 13,122 | 10,844 | 0 | 0 | 0 |
Loss from equity method investment | ||||||||||||||||
- | -5,467 | -6,486 | -4,068 | -4,209 | -4,275 | -3,709 | -3,056 | -2,408 | -1,763 | 0 | 0 | 0 | - | - | - | - |
Other expense, non-cash | ||||||||||||||||
0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Non-cash interest | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 8,050 | 0 | 0 | 0 |
Loss from disposal of property and equipment | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
Unrealized foreign currency remeasurement (gain) loss | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 21 | 8 | -2 | 0 | 0 | 0 |
Gain on extinguishment of convertible loan | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 11,482 | 0 | 0 | 0 |
Changes in: | ||||||||||||||||
Restricted cash | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 |
Accounts receivable | ||||||||||||||||
24,786 | 11 | -513 | -623 | -929 | -2,538 | -2,659 | -5,870 | -4,412 | -531 | 1,119 | 5,460 | 4,707 | 2,818 | 0 | 0 | 0 |
Prepaid expenses and other assets | ||||||||||||||||
-92 | 32,618 | 26,182 | 937 | 3,967 | 3,342 | 6,315 | 7,185 | 6,149 | 4,117 | 681 | -766 | 472 | 1,071 | 0 | 0 | 0 |
Accounts payable and accrued expenses | ||||||||||||||||
5,853 | 5,025 | 4,548 | 7,497 | 9,225 | 12,110 | 10,130 | 5,036 | 2,378 | -831 | -2,394 | -3,231 | -1,744 | 3,860 | 0 | 0 | 0 |
Deferred revenue | ||||||||||||||||
-45,278 | -45,146 | 1,688 | -102 | -103 | -296 | -23,031 | -22,548 | -21,601 | -20,718 | 2,740 | 2,793 | 2,431 | 1,917 | 0 | 0 | 0 |
Deferred rent | ||||||||||||||||
- | - | - | - | - | -709 | -147 | -548 | -202 | -522 | 1,261 | 1,821 | 1,673 | 2,360 | 0 | 0 | 0 |
Operating lease assets and liabilities | ||||||||||||||||
0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Other liabilities, net | ||||||||||||||||
23,576 | 24,983 | 84 | 167 | 30 | 249 | 277 | 80 | 291 | 270 | 3 | 210 | -48 | -17 | 0 | 0 | 0 |
Net cash used in operating activities | ||||||||||||||||
48,239 | 56,677 | 24,929 | -128,455 | -117,288 | -96,239 | -82,709 | -78,613 | -69,370 | -70,093 | -72,217 | -68,625 | -66,257 | -52,860 | 0 | 0 | 0 |
Purchase of property and equipment | ||||||||||||||||
8,578 | 6,684 | 6,732 | 4,966 | 3,315 | 2,773 | 1,978 | 4,277 | 5,084 | 7,814 | 7,837 | 6,352 | 6,069 | 3,016 | 0 | 0 | 0 |
Proceeds from contribution of intellectual property to equity method investee | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 35,000 | 0 | 0 | 0 |
Cash investment in equity method investee | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
Net cash used in investing activities | ||||||||||||||||
-569 | 1,325 | -6,732 | -4,966 | -3,315 | -2,773 | -1,978 | -4,777 | -5,584 | -8,314 | 6,663 | 8,648 | 8,931 | 31,884 | 0 | 0 | 0 |
Proceeds from issuance of common shares, net of issuance costs | ||||||||||||||||
- | 415,019 | 119,250 | 236,750 | 208,350 | 307,053 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Proceeds from exercise of options, net of issuance costs | ||||||||||||||||
15,264 | 15,964 | 5,746 | 5,591 | 8,116 | 8,938 | 9,525 | 8,326 | 5,242 | 2,608 | 0 | 0 | 0 | - | - | - | - |
Proceeds from issuance of convertible loans | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 35,010 | 0 | 0 | 0 |
Net cash provided by financing activities | ||||||||||||||||
406,389 | 430,983 | 124,996 | 242,334 | 216,409 | 315,934 | 318,487 | 130,873 | 127,839 | 2,608 | 93,090 | 88,010 | 148,240 | 183,220 | 0 | 0 | 0 |
Effect of exchange rate changes on cash | ||||||||||||||||
-18 | 15 | -21 | -15 | -26 | -22 | -13 | 1 | 24 | 41 | -176 | -164 | -191 | -235 | 0 | 0 | 0 |
Decrease in cash | ||||||||||||||||
454,041 | 489,000 | 143,172 | 108,898 | 95,780 | 216,900 | 233,787 | 47,484 | 52,909 | -75,758 | 27,360 | 27,869 | 90,723 | 162,009 | 0 | 0 | 0 |
Supplemental disclosure of non-cash investing and financing activities | ||||||||||||||||
Property and equipment purchases in accounts payable and accrued expenses | ||||||||||||||||
2,572 | 1,811 | 0 | 0 | 0 | - | - | 0 | 0 | - | 6,886 | 9,664 | 7,871 | 7,014 | 0 | 0 | 0 |
Equity issuance costs in accounts payable and accrued expenses | ||||||||||||||||
0 | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Conversion of Vertex and Bayer convertible loans and accrued interest | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 61,929 | 0 | 0 | 0 |
Contribution of intellectual property to Casebia | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | 36,380 | 0 | 0 | 0 |